Fusion Pharmaceuticals Inc (FUSN)
21.42
-0.01
(-0.05%)
USD |
NASDAQ |
May 01, 16:00
21.42
0.00 (0.00%)
After-Hours: 18:29
Fusion Pharmaceuticals Cash from Financing (Quarterly): 57.86M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 57.86M |
| September 30, 2023 | 0.328M |
| June 30, 2023 | 24.31M |
| March 31, 2023 | 59.52M |
| December 31, 2022 | 0.131M |
| September 30, 2022 | 28.90M |
| June 30, 2022 | 9.988M |
| March 31, 2022 | 1.709M |
| December 31, 2021 | -0.05M |
| September 30, 2021 | 0.057M |
| Date | Value |
|---|---|
| June 30, 2021 | 0.21M |
| March 31, 2021 | 0.13M |
| December 31, 2020 | 0.056M |
| September 30, 2020 | -2.296M |
| June 30, 2020 | 257.84M |
| March 31, 2020 | 9.907M |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 52.19M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.296M
Minimum
Sep 2020
257.84M
Maximum
Jun 2020
23.61M
Average
0.21M
Median
Jun 2021
Cash from Financing (Quarterly) Benchmarks
| AstraZeneca PLC | 2.028B |
| Landos Biopharma Inc | 0.00 |
| Acasti Pharma Inc | 0.00 |
| Aurinia Pharmaceuticals Inc | -5.577M |
| Edesa Biotech Inc | 0.3057M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.94M |
| Cash from Investing (Quarterly) | -5.242M |
| Free Cash Flow | -85.69M |
| Free Cash Flow Per Share (Quarterly) | -0.2655 |
| Free Cash Flow Yield | -6.10% |